rhenium-186 HEDP

08/01/2003 - "The aim of this study was to determine the pain palliation and the antitumor effect of rhenium-188 HEDP treatments. "
08/01/2003 - "The effectiveness of rhenium-188 HEDP for pain palliation was better in the repeated treatment group (group B), with a response rate and time of response of 92% and 5.66 months, respectively (P =.006 and P =.001). "
05/07/2000 - "[Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain]."
04/01/1996 - "The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with disseminated bone metastases. "
08/01/2007 - "In total, 73% of patients reported pain relief (77% after 188Re-HEDP, 67% after 186Re-HEDP 73% after 153Sm-EDTMP, and 72% after 89Sr). "

11/01/2001 - "Rhenium-188 HEDP to treat painful bone metastases."
06/01/1997 - "Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases."
01/01/2003 - "This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produced nuclide for bone metastases therapy."
01/01/2003 - "Application of rhenium-188 HEDP in bone metastases therapy."
04/01/2011 - "The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases."

04/01/2011 - "The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases."
12/01/2006 - "Whereas, to the best of our knowledge, only few cases of bone metastases from tumors other than prostate and breast treated with [186Re]HEDP have been reported. "
12/01/2006 - "[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast."
12/01/2006 - "Pain palliation with [186Re]HEDP seems highly effective and safe also in patients with bone metastases from cancers other than prostate and breast. "
04/01/2011 - "This study evaluated the tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate ((188)Re-HEDP) in patients with different types of advanced cancer suffering from bone pain caused by osseous metastases. "

01/01/1998 - "The aim of this study was to evaluate the efficacy of rhenium-186 HEDP for pain palliation in patients with bone metastases in breast cancer. "
09/01/1999 - "Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases."
08/01/2007 - "In total, 79 patients (18 with breast cancer and 61 with prostate cancer) were treated (31 patients with 188Re-HEDP, 15 patients each with 186Re-HEDP and 153Sm-EDTMP, and 18 patients with 89Sr). "
01/01/1998 - "As conclusion we found out that therapy with rhenium-186 HEDP can be used complementarily to analgesic therapy and radiation in patients with painful disseminated bone metastases in breast cancer."

11/01/1999 - "Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma."
08/01/2003 - "Compared with single-injection therapy, repeated bone-targeted therapy with rhenium-188 HEDP administered to patients with advanced progressive hormone-refractory prostate carcinoma enhanced pain palliation and improved progression-free and overall survival. "